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Objectives: The anti-inflammatory effects of O-1602 and cannabidiol
(CBD), the ligands of G proteinYcoupled receptor 55 (GPR55), on ex-
perimental acute pancreatitis (AP) were investigated.
Methods: Acute pancreatitis was induced in C57BL mice by intra-
peritoneal injection of 50 Kg/kg cerulein hourly, with a total of 6 times.
Drugs (O-1602, 10 mg/kg, or CBD, 0.5 mg/kg) were given by intra-
peritoneal injection 2 times at 30 minutes before the first injection and
immediately before the fifth cerulein injection. At 3 hours after the last in-
jection, the blood, the lungs, and the pancreas were harvested for the pan-
creatic enzyme activity, myeloperoxidase activity, and pro-inflammatory
cytokines measurement; and the expressions of GPR55 mRNA and
protein in the pancreas were detected.
Results: Cannabidiol or O-1602 treatment significantly improved the
pathological changes of mice with AP and decreased the enzyme activ-
ities, IL-6 and tumor necrosis factor > levels, and the myeloperoxidase
activities in plasma and in the organ tissues. G proteinYcoupled receptor
55 mRNA and protein expressed in the pancreatic tissue, and the ex-
pressions were decreased in the mice with AP, and either CBD or O-1602
attenuated these changes to a certain extent.
Conclusion: Cannabidiol and O-1602 showed anti-inflammatory
effects in mice with AP and improved the expression of GPR55 in the
pancreatic tissue as well.
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Acute pancreatitis (AP) is an inflammatory disease of pan-creas, and it has a potential high morbidity and mortality.
The severity of AP can vary from pancreatic edema with slight
pain to pancreatic necrosis and hemorrhage with multisystem
organ failure, systemic inflammatory response syndrome, and
sepsis.1,2 Uncontrolled activation of proteolytic enzymes and
followed inflammatory response are considered as important
factors in the pathogenesis and development of AP. The detection
of cytokines such as interleukin 6 (IL-6) and tumor necrosis
factor > (TNF->)3Y5 for early assessment and therapeutic targets
of AP has been reported intensively.
The anti-inflammatory potential of cannabinoids has been
a highly interested topic since the discovery of endocannabinoid
system in mammalian. The endocannabinoid system consists of
endogenous cannabinoid receptors, the endogenous ligands, and
the related synthesizing and degrading enzymes.6,7 Evidences
show that cannabinoids participate in inflammatory regulation
and may become new therapeutic medicines in treating in-
flammatory diseases.8Y10 There are clinical reports of cannabis-
induced AP,11,12 but experimental reports confirm the roles of
the 2 ‘‘classic’’ cannabinoid receptors, cannabinoid type 1 (CB1)
receptor and cannabinoid type 2 (CB2) receptor in ameliorating
pain and the modulation of AP.13Y17 It was shown that pre-
administered HU210, a synthetic specific CB1 agonist, protects
against cerulein-induced mouse pancreatitis; otherwise, CB1
antagonist rimonabant attenuated the severity of AP in obese
mice.14,15 One of the endogenous cannabinoids, anandamide,
when administered before the induction of AP, aggravated pan-
creatic damage and administered after the induction of AP, re-
duced the severity of AP, according to the experimental results of
Dembinski et al16; whereas Petrella et al17 got the contrary results
in which pretreatment with anandamide before the induction of
AP worsened the inflammation, but posttreatment improved the
course of the disease.
An orphan G proteinYcoupled receptor 55 (GPR55) found
in 1999 is supported as a novel CB receptor, which acts as a non-
CB1, non-CB2 receptor, or suggested as cannabinoid ‘‘type 3’’
receptor.18Y20 Expression and role of GPR55 in AP are far from
elucidated. Phytocannabinoid-cannabidiol (CBD) is an impor-
tant bioactive component of Cannabis sativa without psycho-
tropic effect and is shown acting as GPR55 antagonist without
binding to CB1 and CB2 receptors.20Y22 The atypical synthetic
cannabinoid O-1602 is an analog of CBD and is identified to
bind strongly to GPR55 with neglect binding capacity to CB1 or
CB2 receptor and acts as a GPR55 agonist.23Y25 In the present
study, based on detection of GPR55 in mouse pancreatic tissue,
an AP mouse model induced by cerulein was treated with CBD
or O-1602. By evaluating the changes of pancreatic histopa-
thology, levels of pro-inflammatory cytokines such as IL-6 and
TNF-> in plasma and in pancreas, and myeloperoxidase (MPO)
activity in lungs and pancreas, and the changes of GPR55mRNA
and protein expressions in mouse pancreas, the possible effects




At least 60 adult C57BL mice (weighting 22Y26 g) were
obtained from Shanghai Experimental Animal Center, Academia
Sinica. Mice were at a 12:12-hour light-dark cycle in sawdust-
coated plastic cages and accessed to standard laboratory chow
and tap water ad libitum at a constant temperature of 23-C T
2-C and relative humidity of approximately 60%. The animals
were fasted for 12 hours before the experiment and were divided
at random into 6 groups with 8 to10 mice in every group: nor-
mal saline (NS) group, CBD group (CBD+NS), O-1602 group
(O-1602+NS), cerulein-induced AP group (AP), CBD-treated
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AP group (CBD+AP), and O-1602Ytreated AP group (O-1602+
AP). All study procedures for animals were complied with in-
ternational guidelines for the care and use of laboratory animals
and approved by the Animal Ethics Committee of Tongji Uni-
versity, Shanghai, China.
Pancreatitis Induction
The mouse AP model was replicated according to the
method described previously.26 In brief, mice in the AP group
received hourly intraperitoneal (IP) injections of 50-Kg/kg cer-
ulein (Sigma Aldrich, Taufkirchen, Germany) for a total of 6
times. In the CBD+AP and O-1602+AP groups, mice got cerulein
with the same procedures as that in the AP group, and 2 additional
IP injections with 0.5-mg/kg CBD or 10-mg/kg O-1602 (Biotrend
GmbH, Cologne, Germany) were given at 30 minutes before the
first and immediately before the fifth cerulein injection. For
control groups of NS, O-1602+NS, and CBD+NS groups,
mice were given isotonic sodium chloride solution instead of
cerulein injection, with the same procedures as that in the AP-
related groups.
Samples Collection and Preparation
At 3 hours after the final injection of cerulein or NS, all
animals were euthanized by decapitation under isoflurane an-
esthesia. The blood was collected in heparin-treated tubes; and
the pancreas and lungs were carefully dissected, rinsed with
isotonic sodium chloride solution, then weighted and divided
into several portions and frozen in liquid nitrogen and stored at
j80 -C until usage, except a portion of the pancreas was fixed in
10% formalin. The blood samples were centrifuged immediately
at 3000 rpm for 10 minutes, and the samples of plasma were put
in tubes and stored at j80-C for later analysis.
Histopathologic Evaluation
Pancreas fixed in 10% formalin as previously mentioned
was paraffin embedded, sliced (5 Hm), and stained by hema-
toxylin and eosin. The slides were studied under a light micro-
scope. Fifteen randomly chosen microscopic fields from 3 slides
of 3 mice in every group were examined by an investigator
blinded to the protocol and the histopathologic score referred
to reports27,28: (1) interstitial and acinar edema: zero, absent; 1,
focal expansion of interlobular septa; 2, expanded expansion of
interlobular septa; 3, focal expansion of intralobular septa; 4,
expanded expansion of intralobular septa; (2) presence of va-
cuolization: zero, absent; 1, less than 20%; 2, 20% to 35%; 3,
35% to 50%; 4, more than 50%; (3) interstitial infiltration of
neutrophils or lymphocytes: zero, absent; 1, 1 to 10 /high-power
field (HP); 2, 11 to 20 /HP; 3, 20 to 30 /HP; 4, more than 30 /HP;
(4) necrosis of acinar cell: zero, absent; 1, 1 to 5 /HP; 2, 5 to 10 /HP;
3, 11 to 15 /HP; and 4, more than 15 /HP. In each group, means of
the scores in edema, vacuolization, infiltration, and necrosis were
presented as results of the final pathological scores.
Amylase and Lipase Activities Detection
Amylase and lipase activities in plasma were measured by
adaptable assay kits (Jianchen, Nanjin, China) and performed ac-
cording to the manufacturer’s instructions. One unit of amylase
activity was defined as degrading 10 mg of amylum in 30 minutes
at 37-C. One unit of lipase activity was defined as degrading
1 Kmol of triglyceride per minute at 37-C. Result of amylase
activity was presented as units per 100 mL of plasma (U/mL), and
lipase activity was presented as units per liter of plasma (U/L).
IL-6 and TNF-> Measurement
Commercial available enzyme-linked immunosorbent as-
say kits (R&D Systems, Abingdon, UK) were used to detect the
levels of IL-6 and TNF-> in plasma or pancreatic tissues. The
tissues were homogenized with a Pro 200 hand-held laboratory
homogenizer (Pro Scientific, Conn) at 2400 rpm in ice-cold
saline. An aliquot of the homogenate was taken for protein de-
termination with the bicinchoninic acid (BCA) protein assay
(Thermo, Rockford, Ill) and the rest of the homogenate, and the
samples of plasma were measured for IL-6 and TNF->, respec-
tively, following the manufacturer’s instructions. Each sample was
detected in duplicate, and the optical density was determined by a
microplate reader (BioTek, Winooski, Vt). IL-6 and TNF-> levels
were calculated as picogram per milliliter of plasma (pg/mL), and
according to the BCA protein assay of the pancreatic tissue, IL-6
level in pancreatic tissuewas expressed in picogram per milligram
protein (pg/mg protein).
MPO Activity Examination
Myeloperoxidase activities in lungs and pancreas were
measured in the study. Tissue samples were homogenized with
the Pro 200 homogenizer at 2400 rpm in ice-cold saline. An
aliquot of this homogenate was taken for protein determination
with the BCA protein assay, and the rest of the homogenate
was used for MPO activity examination by a purchased detection
kit (Jianchen, Nanjin, China), according to the manufacturer’s
instructions. One unit of MPO activity was defined as that de-
grading 1 Kmol of hydrogen peroxide per minute at 37-C. Ac-
cording to the BCA protein assay of the pancreatic tissue, MPO
activity was calculated as units per milligram protein and pre-
sented as percentage of NS control group at last.
Real-Time Quantitative RT-PCR
RNA was extracted from pancreatic tissues using Trizol
reagent (Takara, Shiga, Japan), and a total of 3 Kg of RNA from
each sample was reverse transcripted into first-strand comple-
mentary DNA with Superscript TM II RT Kit (Invitrogen,
Carlsbad, Calif ) according to the manufacturer’s manual. Real-
time quantitative reverse transcription polymerase chain reaction
(PCR) was performed for the detection of the GPR55 mRNA
expression using SYBR Primix Ex TaqTM kit (Takara, Shiga,
Japan) in FTC 3000 PCR instrument (Maple Ridge, Shanghai,
China). Primers and probes were designed and synthesized by
Invitrogen. Polymerase chain reaction amplification was carried
out with the following profile: ‘‘hot star’’ with an initial denaturing
at 95-C for 30 seconds and then 40 cycles of 5 seconds at 94-C
and 31 seconds at 60-C, with the intron spanning primers of
GPR55. The forward primer sequence of GPR55 used here was 5¶-
GGACTCATTGGTACTCCTAAGCTGT-3¶ and reverse sequence
was 5¶-GCAGATCCCAAAGGTCTTCCT-3¶. Glyceraldehyde-3-
phosphate dehydrogenase was as endogenous control to standard
the amount of sample in each reaction, with the forward primer
sequence 5¶-ACCACAGTCCATGCCATCAC-3¶, and the reverse
primer sequence 5¶-TCCACCACCCTGTTGCTGTA-3¶. Assays
were performed in triplicates. The relative quantification value
(double $CT) was calculated from each sample, and the ex-
pression of GPR55 mRNA from the NS group was selected as
calibrator and was set to 1 according to a reference.29
Western Blotting
Pancreatic tissues were homogenized, and the lysate was
analyzed byWestern blotting according to themethod described
previously.30 The primary rabbit anti-GPR55 antibody (Enzo,
Plymouth Meeting, Pa) was used here in a 1:500 dilution and
the internal control of A-actin antibody (Sigma, Taufkirchen,
Germany) in a 1:1000 dilution. The appropriate IRDye secondary
antibody (Rockland, Me) was applied in a 1:5000 dilution and
incubated for 1.5 hours at room temperature. Images taken with
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Odyssey 3.0 imaging system (LI-COR, Lincoln, Neb) were ana-
lyzed by image analysis system for optical density of the protein
bands; and in each group, the GPR55 protein expression was ad-
justed with the corresponding A-actin, respectively. The relative
expression value of GPR55 was presented as percent of the NS
control group.
Immunohistochemistry
G proteinYcoupled receptor 55 protein expression in pan-
creatic tissue was also detected by immunohistochemistry de-
scribed previously.31 The paraffin sections with pancreatic tissues
were dewaxed by regular procedures and dipped in solution of
0.01-mol/L citric acid for 1minute at 95-C, blocked with 5% goat
serum for 30 minutes, and then incubated with rabbit anti-
GPR55 polyclonal antibody (Cayman Chemical, Ann Arbor,
Mich) overnight at 4-C at a dilution of 1:20. Sections were then
followed by biotin-labeled goat antirabbit IgG for 15 minutes at
37-C, and horseradish peroxidaseYlabeled streptavidin (Jinqiao,
Beijing, China) for 30 minutes at 37-C. Finally, the specimens
were stained with diaminobenzidine, nuclear restained with
hematoxylin, and photographed by Leica DM 2500 microscope
(Leica, Wetzlar, Germany). Images were semi-quantified by
Image-pro plus 6.0 (Mediacy, Trenton, NJ). Five nonoverlapping
views were analyzed from each slide and repeated in at least 3
slides from 3 different mice in every group. The average optical
density represented the positive staining intensity and was
expressed as percent of the NS group at last.
Statistical Analysis
Values were obtained from multiple determinations in 5 or
more separate experiments with a minimum of 6 mice, unless
mentioned otherwise. Data were presented as mean T SEM.
Comparisons between 2 sets of data were made by one-way
analysis of variance (SPSS 13.0 software) followed by the
Bonferroni post hoc test for multiple treatments. P G 0.05 was
considered statistically significant.
FIGURE 1. Effects of CBD or O-1602 on pancreatic pathology. Pancreatic tissues were harvested from mice at 3 hours after 6 hourly
injections of cerulein (AP) or NS and stained by hematoxylin and eosin for microscopic analysis; group CBD+NS and O-1602+NS mice
received 2 additional IP injections of 0.5-mg/kg CBD or 10-mg/kg O-1602, respectively, based on NS injection; group CBD+AP and
O-1602+AP mice received 2 additional IP injections of 0.5-mg/kg CBD or 10-mg/kg O-1602, respectively, based on cerulein injection. A,
Representative original pathological figures. B, Scores for edema, vacuolization, inflammation, and necrosis in each group. Results are
expressed as mean T SEM for at least 9 slides from 3 mice in each experimental group. *P G 0.05 compared with the NS group; #P G 0.05
compared with the AP group. Scale bars = 50 Hm. Arrows show the acinous necrosis and/or inflammatory infiltration.
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RESULTS
Effects of CBD or O-1602 on Pancreatic
Histopathologic Alterations
Pancreatic tissues in mice treated with cerulein displayed
histopathological signs of AP characterized by obvious edema in
pancreatic interstices and acinus, acinous vacuolization with slight
infiltration, and parenchymal necrosis, as shown in Figure 1A by
arrows. Either CBD or O-1602 improved the pathological changes
significantly in mice with AP. Cannabidiol or O-1602 alone had
no obvious effects on mouse pancreatic histology in the NS control
mice (Fig. 1).
Effects of CBD or O-1602 on Amylase
and Lipase Activities in Plasma
Amylase and lipase activities in mouse plasma are presen-
ted in Table 1. Compared with the NS control group, cerulein
causes nearly 5 times enhancement of amylase activity and 9 times
increase of lipase activity, and these elevations were significantly
attenuated by either CBD or O-1602 treatment (P G 0.05). The
administration of CBD (CBD+NS group) or O-1602 alone (O-
1602+NS group) had no significant influence on the 2 enzyme
activities compared with the NS control group.
Effects of CBD or O-1602 on TNF-> and IL-6
in Plasma or Pancreatic Tissues
As shown in Figures 2A and B, the levels of TNF-> and IL-6
in plasma were significantly increased in cerulein-induced AP
mice compared with those of the NS control mice (P G 0.05).
Cannabidiol treatment attenuated the increment of TNF-> and IL-
6, and O-1602 affected TNF-> level only. In mouse pancreatic
tissues, IL-6 level in the AP group was also higher than that in the
NS group, and it was attenuated significantly by CBD treatment
but not by the administration of O-1602 (P G 0.05; Fig. 2C). In the
CBD+NS and O-1602+NS groups, CBD or O-1602 alone had no
effects on TNF-> and IL-6 levels in mouse plasma or pancreatic
tissues when compared with that of the NS control group.
Effects of CBD or O-1602 on MPO Activity of
Lungs and Pancreatic Tissue
In the NS control group, MPO activity in tissues of lungs
and pancreas was 1.19 T 0.17 and 0.58 T 0.02 U per gram of
protein, respectively, and both of them increased significantly in
themice of the AP group (P G 0.05). The treatment of either CBD
or O-1602 attenuated the cerulein-induced elevations of MPO
activity (P G 0.05). Both CBD and O-1602 alone (CBD+NS and
O-1602+NS groups) had no effects on the MPO activities in the
lungs or the pancreas of mice (Figs. 3A, B).
Effects of CBD and O-1602 on GPR55 mRNA
and Protein Expression in Pancreas
G proteinYcoupled receptor 55 mRNA expression in mouse
pancreatic tissues was detected by real-time reverse transcription
PCR, and the semi-quantitative data are shown in Figure 4A. G
proteinYcoupled receptor 55 mRNA expression was decreased
markedly in the mice of the AP group when compared with
the mice in the NS group (P G 0.05), and the reduction was at-
tenuated significantly by either CBD or O-1602 treatment. Nev-
ertheless, CBD or O-1602 treatment had no effects on GPR55
mRNA expression in the pancreatic tissues of the mice in the NS
control group.
Western blotting was used to investigate GPR55 protein
expression in the pancreatic tissues, and the representative pro-
file of GPR55 protein is shown in Figure 4B. It was discovered
that GPR55 was on the site of approximately 37 kilodaltons
and A-actin was on the site of approximately 41 kilodaltons. The
TABLE 1. Effects of CBD or O-1602 on Amylase and Lipase Activities in Plasma
Group NS CBD+NS O-1602+NS AP CBD+AP O-1602+AP
Amylase, U/dL 719.7 T 47 673.1 T 39 652.4 T 47 3666.4 T 99* 2804.2 T 114† 2443.0 T 112†
Lipase, U/L 165.7 T 68 192.5 T 15 217.2 T 29 1315.5 T 126* 738.7 T 116† 867.7 T 113†
Blood samples were harvested frommice at 3 hours after the last IP injections. Amylase and lipase activities in the plasmawere detected by adaptable
assay kits as described in the ‘‘Materials and Methods’’. Results are shown as mean T SEM; n = 6-8 per group.
*P G 0.05 compared with the NS group.
†P G 0.05 compared with the AP group.
FIGURE 2. Effects of CBD or O-1602 on TNF-> and IL-6. A, TNF->
level in plasma; B, IL-6 level in plasma; C, IL-6 level in pancreas.
Assay for TNF-> or IL-6 was accomplished with enzyme-linked
immunosorbent assay kit described in the ’’Materials and
Methods’’ section. Results are shown as mean T SEM; n = 6 per
group. *P G 0.05 compared with NS group; #P G 0.05 compared
with AP group.
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findings showed that the expression of GPR55 protein in the AP
group remarkably decreased when compared with that in the NS
group (P G 0.05), and the reduction was attenuated significantly
by either O-1602 or CBD treatment (Fig. 4C). At the same time,
CBD or O-1602 treatment had no effects on GPR55 mRNA
expression in the NS control group.
Immunohistochemistry Detection of GPR55
Protein in Pancreatic Tissue
The brownish staining shown in Figure 5A represent the
expression of GPR55 in the parenchyma of mouse pancreatic
tissue. Together with the semi-quantitative analysis of GPR55
expression shown in Figure 5B, it was further demonstrated that
in the normal pancreatic tissue, GPR55 protein expressed in a
certain amount and seemed not to be affected by CBD or O-1602
alone. However, in the mice of the AP group, there was a de-
creased GPR55 expression in the pancreatic tissue, and CBD or
O-1602 treatment rescued the deduction significantly (P G 0.05).
The changing trends of GPR55 protein expression detected by
Western blotting or immunohistochemistry were highly consis-
tent with that of the GPR55 mRNA expression in the experi-
mental groups.
DISCUSSION
The incidence of AP has been growing since the 1970s and
its treatment is still empiric.32,33 Endocannabinoid system has
become important targets in many fields in the past 20 years, es-
pecially in some inflammatory diseases. Acute pancreatitis is an
inflammatory disease of the pancreas, and inflammatory response
is important in the pathogenesis and development of the disease.
Effects of cannabinoids on AP have been aroused, but the existing
studies mainly focused on the classic cannabinoid receptors and
showed ambiguous and even paradoxical results.11Y17
Evidences have pointed that GPR55 is a receptor of the
endogenous cannabinoids, and a few of peer-reviewed studies
discovered the pharmacology of cannabinoids at GPR55.20,34
It has been reported that GPR55 intensively expressed in many
kinds of organs in mice, including brain, adrenals, spleen, je-
junum and ileum, lung, and kidney, but pancreas has not been
mentioned.20 Our works discovered that GPR55 is expressed in
the pancreatic tissues of mice, as shown in the present study.
Here, we induced mouse AP by IP injection of cerulein,
which is used and accepted widely, and the model displayed
typical signs of AP in histology and enzymology. Using this
model, the early protective roles of the new cannabinoids, O-
1602 and CBD,20,23Y25 were explored. From the results, im-
proved pathological changes and decreased lipase and amylase
activities were observed, which suggest that both CBD and O-
1602 have protective effects on the pancreatic tissues in mice
with cerulein-induced AP.
Proinflammatory cytokine burst is involved in the devel-
opment of AP, and IL-6 and TNF-> have been proposed as better
inflammatory markers of the disease.3Y5 Plasma levels of IL-6
and TNF-> were detected to make clear the anti-inflammatory
roles of O-1602 and CBD. It was demonstrated that the levels of
IL-6 and TNF-> in plasma increased significantly in mice with
AP, but in the study, CBD could reverse the increased levels of
TNF-> and IL-6 both, whereas O-1602 reversed the increment of
TNF-> only. Then, we checked the level of IL-6 in the pancreatic
tissues of mice with AP, and it was also obviously higher; and
CBD, but not O-1602, attenuated the increased levels of IL-6 in
the pancreatic tissue of AP mice, the same effective impact as
they acted on the plasma level of IL-6. It is known that both IL-6
FIGURE 3. Effects of CBD or O-1602 on MPO activity. A,
Myeloperoxidase in lungs. B, Myeloperoxidase in pancreas.
Results are shown as mean T SEM; n = 6 per group. *P G 0.05
compared with the NS group; #P G 0.05 compared with
the AP group.
FIGURE 4. Effects of CBD or O-1602 on GPR55 mRNA and
protein expression by reverse transcription PCR or Western
blotting. A, GPR55 mRNA expression. B, Profiling of GPR55 protein
expression by Western blot. C, Densitometric quantification of
GPR55 protein expression. Results are shown as mean T SEM;
n = 3 per group. *P G 0.05 compared with the NS group; #P G 0.05
compared with the AP group.
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and TNF-> are secreted mostly by T cells, macrophages, neu-
trophils, and endothelial cells; and it has been documented that in
AP, pancreatic acinar cells can produce TNF->, and the peria-
cinar myofibroblasts secrete IL-6.35,36 According to Granger and
Remick,37 TNF-> nicely fits with the model of acinar cell damage
progressing to local inflammation, whereas IL-6 is a marker of AP
but not a direct mediator of cellular or organ injury. The influence
of CBD and O-1602 on pancreatic tissues may be different and
leads to their different effects on levels of TNF-> and IL-6.
Nevertheless, the anti-inflammatory role of CBD and O-1602 was
further demonstrated by their attenuating effects on the increased
activity of MPO in lungs and pancreas of mice with AP.
O-1602 is considered an agonist of GPR55, the new puta-
tive cannabinoid receptor, whereas CBD is considered an an-
tagonist of it.34 However, in the present study, the 2 drugs show
weird similar effects on cerulein-induced mouse AP; especially,
they showed prevention against the pancreatic damage and the
counteract roles on the elevations of the levels of some prein-
flammatory cytokines, and activities of MPO and pancreatic
enzymes, in tissues or in plasma. It has been reported that CBD
produces a plethora of pharmacological effects in the body, in-
cluding antagonizing the CB1 receptor agonists, inhibiting the
activity of fatty acid amide hydrolase, and activating peroxisome
proliferator-activated receptor F, which take part in the inflam-
matory modulation in AP.13Y17,38Y41 These results suggest that
the anti-inflammatory effects of CBD could work by different
mechanisms, except by GPR55-related pathway.
In this study, we found that GPR55 expressed in mouse
pancreatic tissue, and both in gene and protein levels. The ex-
pression was significantly down-regulated in the pancreas of
mice with AP. Cannabidiol or O-1602 reversed the reduction
of GPR55 expression to a certain degree. The administration
of CBD or O-1602 in normal mice did not affect GPR55 ex-
pression. The relationship between the alteration of GPR55
expression in pancreatic tissue and the severity of AP is a valu-
able concern, which needs further work to clarify.
As previously mentioned, CBD is supposed to act as an
antagonist of the GPR55 and O-1602 is a synthetic agonist of
the receptor, and both showed a similar protective role and anti-
inflammatory effect on cerulein-induced mouse AP. To the
contradicted results, further investigations are essential to develop
to get the detail mechanisms and the reasonable explanations by
using specific high selective GPR55 antagonist or GPR55 gene
knock-out mice, etc.
On all accounts, the present study discovered that GPR55
exists in mouse pancreatic tissue. Its ligands, O-1602 and CBD,
FIGURE 5. Immunohistochemistry detection for GPR55 protein expression. A, Photographed images of GPR55 protein by
immunohistochemistry. B, Results of semiquantitative analysis. Five nonoverlapping views were selected from each slide and repeated
in at least 9 slides from 3 mice in each experimental group. Results are shown as means T SEM. *P G 0.05 compared with the NS group;
#P G 0.05 compared with AP group.
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have an anti-inflammatory role and protective effect on the
pancreatic tissues of mice with cerulein-induced AP, and the new
putative cannabinoid receptor GPR55 might be related to the
protective effects against AP.
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